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The intestinal mucosa forms an active interface to the outside word, facilitating nutrient 
and water uptake and at the same time acts as a barrier toward the highly colonized 
intestinal lumen. A tight balance of the mucosal immune system is essential to tolerate 
harmless antigens derived from food or commensals and to effectively defend against 
potentially dangerous pathogens. Interferons (IFN) provide a first line of host defense 
when cells detect an invading organism. Whereas type I IFN were discovered almost 
60 years ago, type III IFN were only identified in the early 2000s. It was initially thought 
that type I IFN and type III IFN performed largely redundant functions. However, it is 
becoming increasingly clear that type III IFN exert distinct and non-redundant functions 
compared to type I IFN, especially in mucosal tissues. Here, we review recent progress 
made in unraveling the role of type I/III IFN in intestinal mucosal tissue in the steady state, 
in response to mucosal pathogens and during inflammation.
Keywords: interferon, intestinal mucosa, colitis, enteropathogens, iFN-λ, type 1 iFN, inflammatory bowel diseases, 
coeliac disease
iNTRODUCTiON
The intestinal tract is a major entry site for viruses and bacteria. Mucosal innate and adaptive immune 
cells are equipped to respond to and fight invading pathogens. At the same time, the intestinal lumen 
is densely colonized by commensal microflora, which at steady state does not provoke an exacerbated 
inflammatory response. The intestinal lumen is separated from the underlying sterile lamina pro-
pria harboring the body’s largest immune cell compartment by a single layer of polarized intestinal 
epithelial cells (IECs). This epithelial cell layer undergoes rapid and perpetual self-renewal without 
disrupting the functional integrity of cell–cell junctions. In addition, IECs not only form a passive 
physical barrier but also participate actively in the immune response against major enteric pathogens 
and cross talk with the commensal flora (1, 2). However, pathogenic viruses, bacteria, and parasites 
exploit opportunities for breaching the epithelial barrier.
Upon infection, host cells communicate by means of production and secretion of signaling mol-
ecules. Interferons (IFN) are a large family of cytokines with diverse functions during a successful 
host defense. The family of type I IFN comprises more than 20 members with multiple IFN-α and one 
IFN-β being the most important. Classically, the most prominent function of type I IFN is to induce 
antiviral immunity, whereas IFN-γ, the only type II IFN, promotes the response to intracellular 
bacteria. However, a vast amount of studies has found that type I IFN are also produced during 
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bacterial infection. In contrast to their action in viral infections, 
their activity against bacteria can be either favorable or detrimen-
tal for the host (3–6).
Recently, a novel family of IFN, the type III IFN or IFN-λ fam-
ily, was described (7, 8). This family consists of IFN-λ1, IFN-λ2, 
IFN-λ3 (also called IL-29, IL-28A, and IL-28B), and IFN-λ4 in 
humans, whereas mice have only two functional genes encoding 
IFN-λ (Ifnl2 and Ifnl3) and two Ifnl1 pseudogenes (9). Similar to 
type I IFN, type III IFN are induced by viral infection and show 
antiviral activity. However, they are structurally distinct from 
type I IFN and interact with a heterodimeric class II cytokine 
receptor consisting of the IFN-λR1 (also called IL-28Rα) chain 
in complex with the IL-10R2 chain, opposed to the type I IFN 
receptor (IFNAR).
A number of studies have addressed the functional impor-
tance of type III IFN compared to type I IFN in the context of 
viral infections (10–15). Less is known about the role of type I 
IFN and almost nothing on the role of type III IFN in the host 
defense against bacterial enteropathogens, intestinal homeosta-
sis, and colitis. Therefore, we review recent progress made on the 
importance of type I and III IFN during enteric viral infections 
and focus on the role of type I IFN in the intestinal mucosal tissue 
during steady state, in response to bacterial infections and during 
inflammation.
iNDUCTiON OF TYPe i AND iii iFN
The induction of type I and III IFN has been recently reviewed 
elsewhere (16), therefore we will only briefly summarize the 
major mechanism leading to IFN expression. Virtually all cells 
are equipped with the machinery to recognize viral infection 
and express type I and III IFN in response. Similar stimuli and 
pathways lead to the expression of type I and III IFN; however, 
differences between cell types as well as in magnitude and kinetics 
have been described (14, 16, 17). Comparable expression patterns 
of type I and III IFN result from a similar requirement of tran-
scription factors for the expression of their encoding genes, such 
as IFN regulatory factors (IRFs) and NF-κB. There are however 
some differences in the promoter region, with IFN-β expression 
relying on the binding of the constitutively expressed IRF-3 to 
its promoter, which allows rapid induction. By contrast, IFN-α 
requires IRF-7 binding, which is an interferon-stimulated gene 
(ISG) itself and needs to be upregulated in most cell types fol-
lowing infection (3). Type III IFN are more dependent on the 
activation of NF-κB (18) and require the combined action of IRFs 
and NF-κB for full induction (19–21).
During systemic viral infections hematopoietic cells are 
the major source of type I IFN. Plasmacytoid dendritic cells 
(pDCs), which are designated as being the “professional” type I 
IFN-producing cells, produce large amounts in response to a 
wide range of viruses, parasites, and bacteria and are particularly 
important in the early phase of type I IFN production (22–24). 
However, depending on the infectious agent, myeloid cells are 
also involved in systemic type I IFN production. During systemic 
Listeria infection, the vast amount of systemic IFN-β production 
is independent of pDCs but seems to be produced by LysM- 
Cre-expressing macrophage/monocyte-like cells including 
TipDCs but not neutrophils (25–27). In the intestinal lamina 
propria, dendritic cells (DCs) as well as mononuclear phagocytes 
produce IFN-β and IFN-α5 in the steady state (14, 23, 28).
Epithelial cells are thought to be the major producer of type 
III IFN at steady state and during enteric viral infection, while 
lamina propria leukocytes (LPLs) also produce type III IFN 
under certain conditions (14, 29). Intraepithelial lymphocytes 
produce IFN-α and IFN-λ upon TCR activation, which contrib-
utes to protection during norovirus infection (30). Moreover, 
Th17 cells are the main source of IFN-λ in psoriatic lesions of 
the skin (31).
Bacteria trigger similar intracellular signaling cascades to viral 
infections and many bacterial infections lead to the production 
of type I IFN [reviewed in Ref. (32, 33)]. Induction of type III 
IFN has been demonstrated only for a limited number of bacte-
rial species. A human epithelial colon cancer cell line expresses 
type III IFN upon infection with Gram-positive bacteria such 
as Listeria monocytogenes (34, 35), Staphylococcus aureus, and 
Enterococcus faecalis but fails to produce considerable amounts 
of type III IFN when infected with Gram-negative bacteria such 
as Salmonella enterica ssp. Typhimurium, Shigella flexneri, and 
Chlamydia trachomatis (35). Induction seems to be cell type, 
species, and gene specific (36, 37).
SiGNALiNG iN ReSPONSe TO iFN
Binding of IFN to their corresponding receptors triggers the 
stimulation of a Janus kinase (JAK)–signal transducer of tran-
scription (STAT) pathway. The type I IFN receptor (IFNAR) 
consists of two subunits, IFNAR1 and IFNAR2. Engagement of 
IFNAR with its ligand ultimately results in the activation of the 
transcription factor complex ISGF3 comprised of STAT1/STAT2 
heterodimers in conjunction with IRF-9 and subsequently the 
induction of ISGs (3, 38).
The type III IFN receptor consists of the unique IFN-λR1 chain 
and the IL-10R2 chain, which is shared with the IL-10 receptor. 
Engagement of this receptor complex results in the activation of 
a signal transduction cascade in a manner highly similar to that 
caused by type I IFN signaling. Interestingly, signaling by type III 
IFN is additionally regulated at the level of receptor expression. 
Whereas IFNAR is ubiquitously present, the IFN-λR1 chain of 
the type III IFN receptor is only expressed in a limited number 
of cell types, preferentially located at mucosal surfaces. Epithelial 
cells in mucosal tissues are a major target of type III IFN (39, 40). 
Additional responsiveness to type III IFN has recently been sug-
gested for a restricted panel of immune cells (9). Type III IFN was 
proposed to have a role in the direct regulation of NK cell effector 
function (41). A suppressive function of type III IFN in autoim-
mune and inflammatory diseases was also proposed recently. In a 
model of collagen-induced arthritis, treatment with type III IFN 
inhibits the recruitment of IL-1β-expressing neutrophils, which 
have been shown to express high levels of IFN-λR1 and respond 
directly to type III IFN (42). In addition, there are controversial 
data on the responsiveness of T cells, DCs, and monocytes to type 
III IFN (9). In human cells, expression of the type III IFN receptor 
seems to be less restricted than in mouse cells and a wider panel of 
immune cells, including B cells, is responsive to type III IFN (43).
TABLe 1 | Role of type i interferons (iFN) and type iii iFN during enteric 
viral infections.
Role of type i iFN Type iii iFN
Rotavirus Type I IFN protect from 
systemic infection and 
heterologous oral infection 
(49, 50)
Type III IFN protect from oral 
homologous infection by restriction of 
replication within intestinal epithelial 
cells (IECs) (12, 29)
Norovirus Type I IFN protect from 
systemic spread of acute 
norovirus infection (48, 51)
Type III IFN protect from persistent 
norovirus infection; treatment with  
IFN-λ clears persistent infection (15)
Reovirus Type I IFN restricts reovirus 
replication in lamina propria 
leukocyte (14)
Type III IFN restricts reovirus replication 
in IECs and fecal shedding (14)
EMCV IFN-α treatment reduces 
titer in hearts during 
systemic infection (47)
Type III IFN does not protect during 
systemic infection (47); type III IFN 
protects from oral infection (52)
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Signaling by IFNs induces the transcription of hundreds of 
ISGs. These include pattern-recognition receptors, antiviral effec-
tors such as myxovirus resistance (Mx) gene 1 and 2, pro-apoptotic 
genes, MHC class I genes, inducible nitric oxide synthase, and 
genes encoding members of the GTPase superfamily which alter 
the maturation of phagosomes to counteract pathogen strategies 
based on survival in intracellular compartments. Moreover genes 
involved in the desensitization to IFNs are also induced, allowing 
cells to recover from the IFN response (38, 44). The importance 
of IFNs in the immediate defense against pathogens has been 
shown by the generation of gene-targeted mice. Mice deficient 
in components of the type I IFN signal transduction pathway are 
highly susceptible to a variety of viruses (5, 45). The role of type I 
IFN in bacterial infections is more complex. Whereas type I IFN 
protect mice against systemic infection with most extracellular 
bacteria tested, they exacerbate disease during infection of mice 
with L. monocytogenes or Mycobacterium tuberculosis (3–6).
eNTeRiC viRAL iNFeCTiONS AND iFN
Studies investigating the functional importance of type I IFN 
versus type III IFN in the context of systemic viral infections 
found a dominant phenotype for type I IFN and only a small 
contribution of type III IFN in the absence of type I IFN. The 
first indication for a tissue-specific role of type III IFN arose 
from studies with organ-tropic viral infections suggesting that 
type III IFN are important in enforcing and strengthening the 
antiviral response at mucosal sites (Table 1) (10–12, 46–48). The 
gastrointestinal tract, lung, vagina, and salivary glands respond 
strongly to systemic IFN-λ expression (40). In the lung and gas-
trointestinal tract, epithelial cells were identified to express high 
levels of the type III IFN receptor and represent the major target 
of type III IFN (11). These findings explain why mice deficient 
for both IFN systems are more susceptible to lung-tropic viruses, 
such as influenza A and B virus, respiratory syncytial virus, and 
severe acute respiratory syndrome coronavirus than single type I 
IFN receptor-deficient mice (11). The remaining part of this sec-
tion focuses on the role of type III IFN in enteric viral infections.
Rotavirus
Rotavirus belongs to the family of reoviridae and infection of 
humans leads to severe diarrhea in children younger than 5 years. 
The susceptibility of infants can be recapitulated in a mouse 
model, where suckling mice are highly susceptible to infection 
compared to adult mice. The strict host cell tropism of rotavirus 
for IECs makes it a clean model to study epithelial-specific effects 
of IFN.
Mice can be infected with a homologous strain of murine 
rotavirus or with a heterologous strain such as rhesus or simian 
rotavirus. Homologous strains are better equipped to evade the 
host immune response, which generally leads to higher viral titers 
and a more severe pathology at a lower infectious dose (49).
A protective role of type I IFN and IFN-γ has been questioned, 
since mice impaired in type I IFN or IFN-γ signaling infected 
with a murine rotavirus strain do not show differences in viral 
load, and treatment with either type I IFN or IFN-γ did not result 
in a clinical benefit (53). However, simian and rhesus rotavirus 
show enhanced systemic replication in mice deficient for type I 
IFN and IFN-γ receptor or STAT1.
By contrast, type III IFN were protective in a homologous 
infection model of suckling and adult mice (12). Of note, a 
very distinct cell tropism for type III IFN responsiveness in the 
intestine was reported: IECs were solely activated by type III IFN 
and are not responsive to type I IFN, whereas cells in the lamina 
propria respond to type I IFN induced during viral infection (12). 
Supporting these findings it was shown that IL-22 augments the 
antiviral effects of type III IFN signaling and contributes to the 
protective effect during homologous rotavirus infection (29). 
However, this model has been questioned by another study 
reporting type I IFN- and type III IFN-mediated protection only 
for heterologous but not for homologous rotavirus infection of 
suckling mice (50). Experimental discrepancies between those 
studies are not apparent suggesting that flora differences between 
mouse facilities or genetic strategy of the knock-out mouse lines 
might impact on the efficacy of IFN signaling. Of note, Lin et al. 
reported age-dependent responsiveness of IECs toward IFNs with 
neonatal IECs being responsive to both type I IFN and type III 
IFN, whereas adult IECs were responsive to type III IFN only (50).
Norovirus
Norovirus is the cause of the majority of non-bacterial gastro-
enteritis in adults. In contrast to rotavirus, the host cell tropism 
of norovirus is broad and not fully characterized. Ex vivo and 
most in vivo studies could not show productive virus replication 
in IECs (54). Phagocytes allow productive virus replication and 
during in  vivo infection, virus was detected in LPLs (54, 55). 
Although the virus does not replicate in IECs, it has been sug-
gested that it translocates across the epithelium or enters the host 
via M cells (56).
Type I IFN and IFN-γ restrict murine norovirus replication 
in macrophages and DCs in vitro (57, 58). In vivo, the antiviral 
activity of type I IFN mediates some protection from systemic 
replication of an acute strain (51) and after high-dose oral 
infection (59). However, local replication in the colon and fecal 
shedding of a persistent norovirus strain is controlled by type III 
IFN. Treatment with type III IFN resolves persistent infection, 
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independent of adaptive immune responses, by acting on non-
hematopoietic cells (15). By contrast, type I IFN controls the 
systemic spread and persistency of the acute norovirus strain 
CW3 by activation of the host DCs (48). These findings demon-
strate the distinct cell-type specificities of type I IFN and type III 
IFN during infection: local protection in the colon through type 
III IFN stimulation of epithelial cells and prevention of systemic 
spread and persistency by type I IFN in myeloid cells.
The commensal bacterial flora was reported to promote noro-
virus persistency in the intestine and antibiotic treatment of mice 
prevented persistent infection with norovirus. The protective 
effect was only observed in the presence of functional type III IFN 
signaling (13). The antibiotic treatment did not alter type III IFN 
signaling and therefore the authors concluded that the microflora 
might render the virus susceptible to the antiviral action of type 
III IFN. Alternatively, the absence of type III IFN signaling might 
increase the host’s vulnerability to persistent viral infection so 
dramatically that minor changes by antibiotic treatment do not 
impact on the overall susceptibility under those conditions.
Reovirus
Reovirus has a broad host cell tropism and replicates in epithe-
lial cells and immune cells of the intestinal mucosa. After oral 
infection, it enters the host via M cells into Peyer’s patches and 
can spread further during infection. Type I IFN produced by 
hematopoietic cells is essential to limit systemic spread of the 
virus and to prevent lethality (60). In a study using type I IFN or 
type III IFN signaling-deficient mice, it was demonstrated that 
type III IFN signaling specifically prevents replication of the virus 
in IECs, whereas type I IFN signaling limits replication in lamina 
propria cells and systemic spread of the virus (14). This study 
confirms the compartmentalized action of IFN in the intestinal 
mucosa and provides an explanation by showing that IECs only 
express low levels of IFNAR (Figure  1). Furthermore, it was 
shown that the production of IFN is cell type specific in that IECs 
produce higher levels of type III IFN and LPLs predominantly 
produce type I IFN.
Taken together, the studies of enteric viral models with 
rotavirus, reovirus, and norovirus show a strong and specific 
responsiveness of IECs to type III IFN (12, 15, 29). Therefore, type 
III IFN might specifically enforce the intestinal barrier against 
enteric viruses and also against viral entry via the intestinal route. 
Additionally, a strong IFN response by type III IFN signaling 
within the epithelial lining prevents viral spreading (12, 14, 15). 
Studies showing that type III IFN treatment protects against oral 
EMCV (52) infection but not from systemic infection (47) sup-
port the conclusion that type III IFN protects the host not only 
from enteric viruses but also from viral entry via the oral route. By 
contrast, the contribution of type I IFN to the epithelial antiviral 
response in the intestine is less clear and conflicting results sug-
gest it to be context dependent (12, 29, 50).
BACTeRiAL iNFeCTiONS
In contrast to viral infections where type I IFN and/or type III 
IFN usually provide an efficient host defense by triggering the 
production of antiviral genes, the role of type I/III IFN in the 
antibacterial response depends on the pathogen and the route of 
infection (3, 4, 61). Type I IFN signaling protects against most 
extracellular bacteria tested but is detrimental in the course of 
infection with a range of intracellular bacteria [Table 2; reviewed 
in Ref. (61)].
Listeria monocytogenes
Most of the pioneering studies unraveling the potential detri-
mental action of type I IFN in the antibacterial response have 
been performed using systemic infection models with L. monocy-
togenes [reviewed in Ref. (4)]. More recent studies, however, have 
proposed that the impact of type I IFN on the outcome of disease 
depends on the route of infection (65).
Mice deficient in IFNAR1, IFN-β, IRF-3, or IRF-7 are more 
resistant to systemic infections with L. monocytogenes than wild-
type mice (25, 62, 64, 78). A number of mechanistic explanations 
for this phenotype exist, including increased death of crucial 
effector cells such as macrophages and T cells in response to type I 
IFN signaling (64, 78, 79), upregulation of IL-10 in an type I IFN-
dependent manner limiting protective inflammatory responses 
(80, 81), and a negative cross talk between type I IFN and IFN-γ 
signaling (82).
In contrast to the clear detrimental effects of type I IFN in 
systemic L. monocytogenes infections, the role of type I IFN in 
oral L. monocytogenes infection has only been addressed by a lim-
ited number of studies mainly due to the lack of a suitable mouse 
model. For the uptake into IECs, specific interaction between 
the Listeria virulence factor internalinA (InlA) and E-cadherin 
expressed on IECs is required. InlA recognizes E-cadherin from 
human but fails to bind the corresponding domain of murine 
E-cadherin (83). A knock-in mouse ubiquitously expressing 
“humanized” E-cadherin provides a model for oral Listeria chal-
lenge (84). Infected germ-free colonies of this mouse line develop 
systemic listerosis, which can be dampened by administration of 
Lactobacilli (85). Lactobacilli treatment downregulates immune 
gene expression and in particular ISGs, which are among the 
most highly induced genes after L. monocytogenes infection (85).
Kernbauer et al. used a “murinized” L. monocytogenes strain 
LO28 expressing altered InlA recognizing mouse E-cadherin to 
show that, in sharp contrast to systemic infection, type I IFN 
signaling in response to both high-dose and low-dose intragastric 
L. monocytogenes infection is beneficial for the host. Diminished 
restriction of bacterial growth in the absence of type I IFN sign-
aling resulted in exacerbated hepatic inflammation and damage 
(65). Different results were obtained by a more recent study using 
an EGDe derivative strain expressing “murinized” InlA (66). 
Contrasting systemic infection, which leads to strong type I IFN 
secretion, oral infection with this strain did not trigger robust 
type I IFN induction in splenocytes even when comparable bac-
terial burdens were present in the spleen. Neither major T cell 
depletion nor increased splenic IL-10 production was observed 
in this model and the detected infection-induced downregulation 
of the IFN-γ receptor on DCs and macrophages was not depend-
ent on type I IFN signaling. Consequently, no major differences 
between wild-type and IFNAR1-deficient mice orally infected 
with L. monocytogenes where detected in this study (66). The 
discrepancies between the Kernbauer and the Pitts study might 
FiGURe 1 | Cell-type-specific responsiveness to type i interferons (iFN) and type iii iFN at the intestinal mucosa. (A) C57BL/6 mice were injected with 
IFN-β (1,000 U) (middle panel) or IFN-λ (1 μg) (right panel) and 3 h later, the small intestine was processed for histological assessment. Staining was performed for 
the interferon-stimulated gene IFIT3 (red) as a marker for IFN response and for the epithelial cell marker E-cadherin (green). (B) Schematic of the IFN production and 
responsiveness at the intestinal mucosa. When type I IFN levels are high, lamina propria cells readily respond with a strong IFN response whereas IECs are rather 
unresponsive but might respond under certain conditions [(A) middle panel; (B) left panel]. In contrast, IECs are the most responsive cells to type III IFN (A,B) right 
panel. Most virus-infected cells express type I IFN. Hematopoietic cells, such as plasmacytoid dendritic cells and macrophages produce the highest amounts of 
type I IFN whereas IECs seem to express preferentially type III IFN. T, T cell; DC, dendritic cell; MΦ, macrophage; IEC, intestinal epithelial cell.
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be explained by different application methods (intragastric infec-
tion compared to natural feeding) or by the use of different strains 
(type I IFN hyper-inducing LO28 versus EGDe). In addition, dif-
ferences in the microbiota due to the housing conditions might 
influence the outcome of infection.
Salmonella enterica Typhimurium
Salmonella enterica serovar Typhimurium causes gastroenteritis 
and is one of the most frequent causes of bacterial foodborne 
disease in Western countries, representing a major economic 
problem (86).
Oral infection of laboratory mice with S. Typhimurium causes 
typhoid-like symptoms without clinical signs of gastroenteritis 
and can be used to study genetic determinants of systemic infec-
tions. IFN-β−/− mice show increased resistance to S. Typhimurium 
in lethality and bacterial spread in this model (67, 68).
The natural microbiota of the mouse gut is able to outcompete 
Salmonella to occupy this ecological niche. Thus, a new model of 
typhlocolitis was developed employing streptomycin treatment 
to deplete commensal bacteria and to overcome the colonization 
resistance of mice. This infection model leads to a rapid induction 
of inflammation in cecum and colon (87, 88).
An influence of type I IFN signaling on the immune response 
to S. Typhimurium infection has been suggested during the 
analysis of Usp18-deficient mice (69, 89). USP18 is a deubiqui-
nating protease with de-ISGylation activity specific for ISG15. 
It also limits JAK–STAT activation and is thus involved in the 
negative regulation of type I IFN signaling. During systemic 
Salmonella infection, increased STAT1 activation correlated 
with impaired STAT4 activation and reduced IFN-γ production, 
and Usp18 mutant mice are more susceptible to systemic (i.e., 
typhoid) S. Typhimurium infection (89). By contrast, in the 
TABLe 2 | Role of type i interferons (iFN) in intestinal inflammation and bacterial infections.
Mouse strain Phenotype—type i iFN Reference
 BACTeRiAL iNFeCTiON
Listeria monocytogenes
IFNAR1−/−-, IFN-β−/−, IRF-3−/−, IRF-7−/− Type I IFN signaling is detrimental during systemic infection (25, 62–64)
IFNAR1−/− Kernbauer et al. showed that type I IFN signaling during oral infection with the potent type I IFN inducing LO28 
strain is beneficial for the host. By contrast, Pitts et al. did not observe any role for type I IFN during oral infection 
with the EGDe strain
(65, 66)




IFN-β−/− Lack of IFN-β mediates increased resistance to lethality during oral S. Typhimurium infection (67)
IFNAR−/− IFNAR deficiency leads to increased resistance to oral S. Typhimurium characterized by decreased bacterial 
spread and weight loss but similar intestinal pathology. In accordance, type I IFN induction due to influenza 
coinfection exacerbates the disease and CFU but decreased intestinal immunopathology
(68) 
USP18−/− During Salmonella infection, Usp18-mutant mice are more susceptible to systemic (i.e., typhoid) S. Typhimurium 
infection. By contrast, in the streptomycin-induced model of typhlocolitis, mutant Usp18 mice display lower 
pathology scores, low IFN-γ production but upregulated type I IFN signaling compared to control mice, resulting 
in earlier systemic dissemination of the bacteria and decreased survival
(69)
Yersinia enterocolitica
TRIF−/− IFN-β treatment protects TRIF−/− mice from Y. enterocolitica lethality (70)
 COLiTiS MODeLS
T cell transfer colitis
IFN-α treatment Ameliorates T cell transfer colitis (71)
IFNAR−/−host IFNAR deficiency in the host cells exacerbates colitis; indirect effect on maintenance of Foxp3+ Tregs (23)
IFNAR−/− T cells Induction of colitis by IFNAR−/− T cells similar to wt T cells, however, boosting type I IFN by poly(I:C) treatment 
attenuates T cell transfer colitis in a T cell-(IFNAR-)dependent manner
(23, 72)
IFNAR−/− Tregs Conflicting findings on the role of IFNAR signaling in Tregs for protection from T cell transfer colitis (23, 71)
Dextran sodium sulfate (DSS) colitis





IFNAR1−/− Type I IFN signaling suppress acute DSS colitis but delays the resolution (73, 75)
Villin-Cre IFNAR1fl/fl IFNAR deficiency in intestinal epithelial cells results in similar susceptibility to DSS colitis as wt; increased tumor 
burden in DSS + azoxymethane model (due to microbiota alterations)
(76)
IL-28Rα−/− Increased susceptibility in IL-28Rα−/−, same as IL-28Rα−/− IFNAR1−/− DKO indicating dominant role of type III IFN (77)
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streptomycin-induced model of typhlocolitis, mutant Usp18 
mice display lower pathology scores, low IFN-γ production but 
upregulated type I IFN signaling compared to control mice, 
resulting in earlier systemic dissemination of the bacteria and 
decreased survival (69).
Interestingly, influenza-induced type I IFN suppress host 
intestinal immunity leading to increased susceptibility to second-
ary Salmonella-induced colitis (68). Influenza-induced type I IFN 
strongly inhibited the induction of antimicrobial and inflamma-
tory genes such as IFN-γ, S100A9, and lipocalin-2 in response to 
secondary S. Typhimurium infection causing increased intestinal 
colonization and increased bacterial dissemination but reduced 
immunopathology (68).
In summary, these studies suggest a detrimental effect of 
type I IFN on the growth and dissemination of bacteria in 
Salmonella-induced typhlocolitis whereas it limits intestinal 
inflammation. These effects are more obivous when type I IFN 
production is boosted by influenza infection or polyI:C treatment 
(68). Additional studies are required to determine the direct 
and indirect effects of type I IFN on S. Typhimurium-induced 
typhlocolitis. Moreover, the role of type III IFN in this model has 
yet to be addressed.
Other enteric Bacterial infections
The role of type I or III IFN in other enteric bacterial infections 
[e.g., enteropathogenic (EPEC) and enterohemorrhagic (EHEC) 
Escherichia coli, Citrobacter rodentium, Campylobacter jejuni, 
or Yersinia enterocolitica] has not been extensively addressed in 
in vivo infection models.
Citrobacter rodentium and EPEC developed immune evasion 
strategies targeting type I IFN signaling, suggesting a protective 
effect of type I IFN against those pathogens. C. rodentium has 
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been reported to actively inhibit epithelial type I IFN production 
employing a mechanism depending on the type III secretion 
system (T3SS) (90). Furthermore, it also reduces type I IFN 
signaling by decreasing nuclear translocation of phosphorylated 
STAT1 even after co-stimulation with IFN-β (90).
Infection of a colon cancer cell line with EPEC results in a 
modest IFN-β production, which regulates tight junction proteins 
such as claudin 1 and occludin to maintain barrier function (91). 
Using a distinct mechanism to C. rodentium, an EPEC T3SS 
effector, NleD, reduces IFN-β induction by inhibition of RNase 
L, ultimately resulting in evasion of antibacterial activities and 
disruption of barrier function (91).
Type I IFN also play a protective role during oral Y. entero-
colitica infection. TRIF-deficient mice are highly susceptible to 
Y. enterocolitica infection with increased bacterial spread and 
lethality. This could be prevented by IFN-β treatment of TRIF-
deficient mice and IFNAR blocking of wild-type mice recapitu-
lates increased bacterial burden (70).
Campylobacter jejuni infection of murine DCs leads to TLR4/
TRIF-dependent activation of IRF-3 and secretion of type I 
IFN and cooperative signaling through both TLR4/MyD88 and 
TLR4/TRIF pathways is required for full Th1 priming ability 
(92). Interestingly, production of type I IFN and other cytokines 
in splenic tissue is significantly increased by lipo-oligosaccharide 
(LOS) sialylation (93).
Whether type I IFN and/or type III IFN responses to sia-
lylated C. jejuni have a role in oral infection models of mice 
awaits further investigation. Recently, novel mouse models have 
been developed relying on the eradication or modification of 
the murine gut microbiota using broad-spectrum antibiotic 
treatment and subsequent re-association with a complex human 
microbiota. This approach leads to stable colonization with C. 
jejuni and a proinflammatory response in the colons of infected 
mice (94). Hopefully, these models will provide the necessary 
tools to answer the questions of an in vivo importance of type 
I IFN and/or type III IFN in the mucosal immune response to 
C. jejuni. This will be of particular importance since type I IFN 
responses have also been observed in former C. jejuni-infected 
patients suffering from Guillain–Barré syndrome (GBS), an 
autoimmune neuropathy where infection with C. jejuni is the 
most common predisposing factor (95). C. jejuni LOS activates 
TLR4 and high responsiveness of DCs isolated from former GBS 
patients was hypothesized to influence the development of GBS. 
Indeed, although a strong variability in DC responses to LOS 
was observed, the frequency of CD38, CD40, and type I IFN 
high responders was significantly increased in the C. jejuni-
related former GBS patients compared to controls (95).
iMPORTANCe OF TYPe i AND iii iFN 
SiGNALiNG FOR iNTeSTiNAL 
HOMeOSTASiS
A Role for Type i and iii iFN in Shaping the 
Microbiota
Intestinal homeostasis is dependent on the tight interplay 
between the host and commensal flora. The flora directly protects 
the host from intestinal pathogens by competition for nutrients 
and space. Furthermore, commensal bacteria are important for 
the development of the immune system and maintenance of the 
barrier. The host immune system has also a great influence on 
the composition of the microbiota (96). Several studies have sug-
gested that IFN signaling influences cross talk between the host 
and the flora.
It has long been recognized that the microbiota of different 
inbred mouse strains changes over time despite shared origin, 
which has been attributed to host genetic factors (97). Gene-
expression analysis of the colonic mucosa revealed that IFN-
responsive genes are differentially regulated between the different 
mouse strains and might thus contribute to microbiota regulation 
(97). Indeed, microbiota analysis of mice with selective ablation 
of type I IFN signaling in the intestinal epithelium revealed 
changes of the microbiota composition if littermates were housed 
separately for 8–12 weeks (76). However, it is not known whether 
this is a direct effect of type I IFN signaling by the epithelium and 
what the mechanistic relationship is.
The community stability of the gut microbiota might also 
depend on IFN signaling (98). IRF-9-deficient mice unable to 
respond to either type I IFN or type III IFN displayed a signifi-
cantly higher temporal variation than wild-type mice, which was 
accompanied by an increased presence of T cells and neutrophils. 
However, STAT1-deficient mice, which classically are unable to 
respond to type I IFN, type III IFN, and IFN-γ, were not signifi-
cantly different from wild-type mice implicating that a previously 
unrecognized pathway might be involved (98). Indeed, a role 
for IRF-9 in non-canonical IFN signaling and beyond the IFN 
response has been suggested (99).
Recently, Deriu et al. reported that systemic influenza-induced 
type I IFN production significantly alters the intestinal micro-
biota profile (68). While under their experimental conditions 
uninfected wild-type and IFNAR1-deficient mice displayed 
similar fecal microbial communities, influenza infection-induced 
type I IFN signaling resulted in a depletion of indigenous seg-
mented filamentous bacteria and enhanced colonization with 
Enterobacteriaceae (68).
Type III IFN signaling on its own does not have a strong effect 
on the flora composition, as 16S rDNA sequencing of the V4 
region of fecal pellets from wild-type or IFN-λR1−/− mice revealed 
similar bacterial class composition (13). It is important to note 
that microbiota studies are difficult to control and generalizations 
from one specific study should be drawn carefully as major differ-
ences have been found between mouse facilities.
A Role for Type i and iii iFN in Shaping 
intestinal Homeostasis
Upon colonization of germ-free mice with a two-component bac-
terial community, IFN-responsive genes are strongly upregulated 
in cecal epithelia (100).
Several studies have also demonstrated a role for commensal-
induced tonic type I IFN signaling in the steady state to keep 
the host in a state of alertness against a systemic viral infection 
(101–103). Mononuclear phagocytes isolated from non-mucosal 
lymph nodes of germ-free mice are unable to upregulate type I 
IFN genes after stimulation with microbial ligands and thus fail 
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to prime NK cells and antiviral immunity (102). A second study 
came to similar conclusions demonstrating decreased antiviral 
gene expression and defective ISG expression of macrophages 
from antibiotic-treated mice (101). The nature of the commensal 
bacterial species or microbial product responsible for the tonic 
type I IFN production is unknown and its identification remains 
a future challenge.
Recently, a connection between the increased susceptibility 
of liver cirrhosis patients to bacterial infections and tonic type I 
IFN signaling was made (81). In a murine model of liver fibrosis, 
translocated gut bacteria induced the expression of a tonic type I 
IFN signature in the liver, which in turn conditioned myeloid cells 
to produce vast amounts of type I IFN upon subsequent systemic 
infection with L. monocytogenes. Type I IFN signaling resulted 
in the production of IL-10 by myeloid cells, which hampered 
antibacterial immunity. Key findings of the murine model such 
as a type I IFN signature in cirrhotic livers and myeloid IL-10 
production could also be recapitulated in human patient material. 
Thus, tonic type I IFN signaling induced by the translocated gut 
microbiota can also have detrimental effects (81).
Plasmacytoid dendritic cells are known to be important 
producers of type I IFN after viral infections and treatment with 
bacterial nucleic acids. Interestingly, pDCs derived from Peyers’s 
patches are incapable of producing significant amounts of type 
I IFN after stimulation with CpG-enriched oligodeoxynucleo-
tides while producing IL-12 (104). Thus, although tonic type I 
IFN production by myeloid cells fulfils important functions to 
maintain basal levels of ISGs (81, 101, 102), the mucosal micro-
environment prevents production of vast amounts of type I IFN 
by pDCs—presumably to prevent harmful immune responses to 
commensal microorganisms (104). Other sources of type I IFN 
in the GALT are stromal cells. Indeed stroma-derived type I IFN 
has been shown to induce APRIL and BAFF expression by pDCs, 
which facilitates T cell-independent IgA production by mucosal 
B cells (105).
Of note, the expression of ISGs at steady state seems to be 
driven by type I IFN and type III IFN in a cell type-specific man-
ner. The cells of the lamina propria are mainly activated by type 
I IFN whereas IECs respond mainly to baseline levels of type III 
IFN due to low IFNAR expression on IECs, which is in accord-
ance with the response pattern observed during viral infection 
(Figure  1) (14). Furthermore, the role of altered type I IFN 
signaling on IECs was addressed by several groups (50, 76, 106).
Tschurtschenthaler and colleagues reported that the lack 
of type I IFN signaling in IECs leads to a hyperproliferative 
phenotype (76). Particularly the secretory cell types Paneth and 
goblet cells are expanded in a setting where IECs are the only cells 
impaired in type I IFN signaling (Villin-Cre Ifnarfl/fl). Although 
this study suggests that type I IFN signaling occurs in IECs, the 
proliferative phenotype is secondary due to alterations of the 
microflora, as cohousing of the mice resolved the differences (76).
Katlinskaya et al. used a model of decreased IFNAR degra-
dation in IECs to study type I IFN signaling outcome in IECs 
(107). CK1α can phosphorylate IFNAR1, which subsequently 
leads to its degradation (108). Genetic ablation of CK1α in IECs 
leads to increased IFNAR levels and elevated type I IFN signal-
ing in the epithelium. CK1α deficiency also results in β-catenin 
activation, which leads to hyperproliferation of the epithelium 
and loss of barrier function where type I IFN signaling is addi-
tionally blocked. Elevated type I IFN signaling, however, inhibits 
β-catenin-driven proliferation and induces apoptosis maintain-
ing barrier integrity (107).
In another model of chronically elevated levels of systemic 
type I IFN, epithelial cell turnover was increased in various 
tissues including the intestine (106). This effect was not due to 
direct signaling of type I IFN in epithelial cells but by induction 
of Apol9a/b in macrophages or stromal cells that subsequently 
promoted the turnover of epithelial cells (106).
Taken together, epithelial type I IFN signaling seems to have 
a pleiotropic effect depending on levels of receptor expression, 
ligand abundance, microflora, and tissue context.
iMPORTANCe OF TYPe i/iii iFN 
SiGNALiNG UNDeR iNFLAMMATORY 
CONDiTiONS
Experiments employing different murine models of colitis such 
as dextran sodium sulfate (DSS) colitis or the T  cell transfer 
model have provided a complex picture of the role of type I/
III IFN in intestinal inflammation. Administration of DSS in 
the drinking water leads to disruption of the epithelial barrier 
and an inflammatory reaction to microbial patterns and food 
antigens. The T cell transfer model on the other hand relies on 
the transfer of naive CD4+ T cells into immune-deficient mice 
(e.g., RAG−/− mice), which undergo activation and proliferation 
in response to microbial products to provoke inflammatory 
colitis when a suppressive T  cell population (Foxp3+ Tregs) is 
absent (109, 110).
Katakura et al. investigated the role of type I IFN induction 
after administration of CpG ODN in experimental colitis (73). 
Mice deficient in type I IFN signaling are resistant to the CpG 
ODN-mediated effect and are more susceptible to DSS treatment 
than wild-type mice, suggesting a protective effect of type I IFN 
signaling.
By contrast, a therapeutic approach employing a transgenic 
Lactobacillus acidophilus strain constitutively expressing IFN-β 
(La-IFN-β) failed to protect against DSS-induced colitis but 
exacerbated the disease (74). Colitic mice pretreated with 
La-IFN-β displayed increased production of proinflamma-
tory cytokines and decreased numbers of Tregs in their small 
intestine. In vitro, maturation of bone-marrow-derived DCs 
with La-IFN-β resulted in a threefold reduction of IFNAR1 
and an impaired ability to induce Tregs (74). Thus, although a 
correlation between downregulation of IFNAR1 on DCs and 
exacerbation of colitis was observed, pretreatment of colitic mice 
with La-IFN-β surprisingly also resulted in increased intestinal 
damage (74). These results suggest that a tight regulation of 
type I IFN signaling is important for the balance of intestinal 
homeostasis.
The effect of type I IFN in experimental colitis might depend on 
the severity of inflammation and opposing roles in specific phases 
of intestinal damage and inflammation have been proposed (75, 
111). At high DSS concentrations, type I IFN signaling protected 
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against acute intestinal damage presumably by suppressing the 
release of IL-1β from colonic MHC class II+ cells (75). In the 
recovery phase after DSS treatment, type I IFN signaling resulted 
in delayed recovery from intestinal inflammation accompanied 
by increased cell apoptosis as well as an increase in chemokine 
production and subsequent infiltration of neutrophils and inflam-
matory monocytes (75). The potential of type I IFN signaling to 
either suppress acute colitis or delay the recovery might provide 
an explanation for the varying effects of type I IFN treatment on 
inflammatory bowel diseases (IBD) patients.
Several groups have analyzed the effect of type I IFN signaling 
on T cells (23, 71, 72, 112).
CD69 is suggested to be a regulator of intestinal homeostasis 
and is highly expressed on intestinal CD4+ T cells, which at steady 
state is driven by the microflora but can be further induced by 
type I IFN signaling (72, 113). Poly(I:C) treatment during T cell 
transfer colitis attenuates colitis by IFNAR-dependent CD69 
induction on T  cells, which leads to downregulation of proin-
flammatory cytokine levels (72).
Furthermore, Lee et al. identified a protective role of T cell type 
I IFN signaling by regulating the expression of Foxp3 and the sup-
pressive effect of Tregs (71). Whereas Tregs isolated from wild-
type mice suppressed colitis when cotransferred with naïve CD4+ 
T cells, the same cell population derived from IFNAR1−/− mice 
failed to do so. Although Tregs undergo normal development 
in IFNAR1−/− mice, the cells acquire a dysfunctional phenotype 
accompanied with reduced Foxp3 expression when cotransferred 
with naive CD4+ T cells into RAG1−/− recipients. Administration 
of recombinant IFN-α ameliorated T-cell-dependent colitis by 
augmenting the number of Foxp3+ Tregs suggesting a potential 
therapeutic application of type I IFN in intestinal inflammation 
(71, 72, 113).
By contrast, several studies suggested an indirect effect of TLR9 
ligands and type I IFN signaling for protection in T cell-mediated 
experimental colitis (23, 99, 112). While a role for B  cells was 
excluded, colitis-reducing effects of CpG ODN were mediated by 
CD11c+ cells and required functional type I IFN signaling in a 
model of T cell transfer colitis (112).
Kole et  al. showed that colon mononuclear phagocytes 
deficient in type I IFN signaling failed to produce regulatory 
cytokines such as IL-10, IL-27, and IL-1RA in response to TLR 
activation. Furthermore in the T  cell transfer colitis model, 
IFNAR signaling of host hematopoietic cells was important to 
limit effector cell expansion and to promote the stabilization of 
Foxp3+ Tregs (23).
Intestinal epithelial cells and in particular Paneth cells have 
also been proposed to be a target of type I IFN signaling in 
the intestine (76, 114). Paneth cells are epithelial cells located 
at the bases of small-intestinal crypts specialized in secretion 
of antimicrobial peptides and factors to sustain epithelial stem 
cells and progenitor cells (115). Mice with a specific deletion of 
IFNAR1 in IECs display expansion of Paneth cell numbers and 
epithelial hyperproliferation when compared with wild-type 
littermates. Although epithelial-specific deletion of IFNAR1 
did not impact on the severity of spontaneous or DSS-induced 
intestinal inflammation, they exhibited increased tumor burden 
in the azoxymethane/DSS model of colitis-associated colon 
cancer (76), Both spontaneous epithelial hyperproliferation 
and tumor promotion are dependent on the microbial flora, 
since differences between wild-type and IEC-specific IFNAR1-
deficient mice were only apparent if the mice were housed 
separately (76).
Human and murine IECs display high responsiveness to type 
III IFN treatment (12, 116). A recent study has demonstrated a 
protective role of type III IFN signaling in DSS-induced colitis 
(77). Mice deficient for the type III IFN receptor lost significantly 
more weight and suffered from significantly increased intestinal 
damage after DSS treatment when compared to WT controls. 
Additional loss of the type I IFN receptor did not change the 
pathology scores compared to the single loss of type III IFN 
receptor, emphasizing a prominent role of type III IFN signaling 
in this model. The protective effect of type III IFN signaling is 
independent of potential changes in the microbiota since the 
same results were obtained when wild-type and type III IFN 
signaling-deficient mice were cohoused for 3 weeks (77).
TYPe i iFN AND iBD
The IBD, comprising Crohn’s disease (CD), and ulcerative colitis 
(UC) are chronic debilitating inflammatory disorders of the 
gastrointestinal tract. IBD affects about 0.2% of Western popula-
tions and there is no current cure, typically requiring long-term 
treatment with immune suppressive agents and, in many cases, 
surgical intervention. Although the etiology remains unclear, 
IBD is thought to arise due to aberrant immune responses to 
components of the commensal bacterial microbiota (117). 
Recent genome-wide association studies have identified more 
than 160 genetic susceptibility loci for IBD, with affected genes 
involved in immunity and in barrier function (118). Many of 
those single-nucleotide polymorphisms (SNPs) are found in 
genes associated with pathogenic cytokine circuits, such as the 
Th17/IL23 circuit, IL-10, and type I IFN-I signaling (119). The 
majority of signaling mediators are shared between different 
cytokine signaling cascades and therefore exact determination 
of the relevant pathways is impossible from the genetic data 
only. Interestingly, several of the IBD-associated genes are also 
involved in the type I IFN signaling pathway. The rs2284553 SNP 
is commonly associated with the IFNGR2 gene but could also 
affect the IFNAR1 gene (118). JAK2, TYK2, STAT1, and STAT3 
genes harbor identified SNPs and are signaling mediators in 
many cytokine pathways such as IL-22, IL-10, and also type I/III 
IFN. Furthermore, polymorphisms in the MDA5 or IRF5 gene 
might alter the production of type I/III IFN (118). Although the 
type I IFN signaling network is not one of the major players in 
IBD pathology, slight alterations may contribute to the imbal-
anced immune response at the lamina propria, as suggested by 
mouse studies.
Indeed, Giles and colleagues analyzed the responsiveness of 
T  cells from healthy controls and IBD patients to IFN-β and 
found that IFN-β signaling modulates colonic T cell responses 
in a context-dependent manner. Human colonic T  cells were 
responsive to exogenous IFN-β and endogenous IFN-β influ-
enced the cytokine profile of ex vivo cultured T cells. T cells from 
healthy controls produced decreased levels of IL-10 in the absence 
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of IFN-β signaling whereas T cells from IBD patients produced 
elevated levels of proinflammatory cytokines (120).
Interferons-β has been approved for the treatment of multiple 
sclerosis (MS); however, a subset of patients does not respond 
to the treatment. Axtell and colleagues analyzed the effect of 
IFN-β on different Th subsets and found that IFN-β treatment in 
a mouse model of EAE attenuates disease development in a Th1-
driven pathology, but had no effect or even exacerbates pathology 
in Th17-driven disease. Furthermore, they could correlate high 
IL-17-F serum levels in MS patients to non-responsiveness toward 
IFN-β treatment. These findings confirm the immunomodula-
tory role of IFN-β but also demonstrate the diverse consequences 
it has in different context with opposing effects within a Th1 and 
Th17 setting (121).
Despite the varying results from mouse studies on the role 
of type I IFN in colitis and the discrepancy between type I IFN 
effects on suppressing acute colitis and delaying recovery (74, 
75), type I IFN have been suggested for the treatment of IBD. 
Several small studies have evaluated the consequences of IFN-
β1a in IBD patients with varying results (122–128). Although 
small pilot studies suggested a beneficial outcome of type I IFN 
treatment of IBD patients (123, 124), a placebo-controlled, 
double-blind study on Crohn’s patients in remission did not find 
any improvement by IFN-β1a treatment on the maintenance 
of remission (127). Also two randomized placebo-controlled 
studies in UC patients with active disease could not show 
a beneficial effect of IFN-α or IFN-β1 treatment on disease 
remission (125, 126). A small study analyzing cytokine levels 
before and after treatment with IFN-β1a found a correlation 
between responsiveness and reduction of IL-13 levels in UC 
patients. The unresponsiveness to IFN-β1 treatment correlated 
with elevated levels of IL-17 in accordance with the findings in 
MS patients (121, 128).
Taken together, these studies do not support a beneficial 
outcome of type I IFN treatment during IBD. This conclusion 
was also drawn in a recent intervention review analyzing all 
trial data published on the effectiveness of type I IFN treatment 
on remission in UC patients (129). However, considering the 
analysis of IFN-β non-responsiveness of patients with MS 
(121), context-specific responsiveness of T cells toward type I 
IFN (120), and controversial findings in mouse studies (23, 74, 
75), the effect of the treatment might vary between Th profiles 
of patients and a careful pre-selection of patients would be 
required. Further studies with sufficient patient numbers and 
thorough analysis of immunological and disease parameters are 
required.
TYPe i iFN AND CeLiAC DiSeASe
Celiac disease is a small-intestinal enteropathy characterized 
by an aberrant T cell-mediated immune response of susceptible 
individuals to dietary gluten. The pathogenic adaptive immune 
response is initiated by the interplay between gluten and the 
MHC class II molecules HLA-DQ2 and DQ8 and is character-
ized by a potent Th1 response. The excessive tissue destruction 
is further driven by a severe IEL hyperplasia targeting IECs. 
Histologically, celiac disease is characterized by villous flattening, 
crypt hyperplasia, and IEL infiltration. Affected individuals can 
present with very variable symptoms ranging from asympto-
matic to severe symptoms ascribed to impaired absorption of 
nutrients (130).
The strongest genetic factor for the disease is HLA-DQ2 and 
DQ8; however, it is now recognized that further immune-regula-
tory or activating factors are required for disease establishment. 
Several celiac disease susceptibility loci in genes associated with 
innate immune responses have been identified, suggesting a role 
for innate immunity in the development of the disease (131).
An influence of type I IFN on the development of celiac 
disease has been widely discussed. Indeed, a number of case 
studies reported on the development of diarrhea and the onset of 
celiac disease during treatment with IFN-α for chronic hepatitis 
C patients (132–137). A retrospective study of 534 hepatitis C 
patients with or without symptoms of celiac disease showed an 
activation of silent celiac disease in the majority of patients posi-
tive for transglutaminase antibodies while on IFN therapy (138). 
The immunomodulatory properties of type I IFN might worsen 
underlying autoimmune disorders and monitoring of hepatitis C 
patients for celiac disease before starting an IFN therapy has been 
suggested. A potential role of cotreatment with ribavirin, which 
promotes a Th1-mediated immune response while suppressing 
Th2 responses, has also been discussed (133).
The high prevalence of celiac disease in HCV patients treated 
with IFN-α was investigated in a study including 210 chronic 
hepatitis C patients. This study failed to detect a significant 
association of celiac disease and HCV infection and in addition 
came to the conclusion that IFN-α therapy per se does not trigger 
celiac disease in patients negative for endomysium (EMA) and 
tissue transglutaminase (139). It does not however rule out that 
IFN-α treatment might trigger the development of celiac disease 
in susceptible individuals.
To investigate the underlying mechanisms, explant cultures 
of human fetal gut were analyzed after activation of T cells with 
anti-CD3 and IFN-α. While single treatment with either anti-
CD3 or IFN-α alone did not trigger any profound changes, the 
combination of both resulted in enhanced Th1 responses and 
crypt cell hyperplasia associated with enhanced STAT1, STAT3, 
and FYN phosphorylation. IFN-α treatment might thus facilitate 
activation of Th1-reactive cells and trigger immunopathology 
(135, 140).
Onset of celiac disease-like symptoms have also been observed 
in a case of chronic myeloid leukemia treated with IFN-α again 
suggesting a role of type I IFN in promoting Th1 responses to 
gluten (135). Also, IFN-α protein was detected in duodenal tissue 
of celiac disease patients but not in control samples (135).
Further studies are required to determine whether a direct link 
exists between type I IFN signaling and celiac disease.
CONCLUDiNG ReMARKS
Although important progress has been made in recent years, 
additional studies are required to deepen our understanding of 
the role of type I IFN and type III IFN in the gut. Type I IFN 
signaling in enteric viral infections is mostly protective, whereas 
it can be detrimental in certain enteric bacterial infections. The 
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